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Abstract: Long chain fatty acids (LCFAs) provide 70-80% of the energy for cardiac contractile activity. LCFAs are also 
essential for many other cellular functions, such as transcriptional regulation of proteins involved in lipid metabolism, 
modulation of intracellular signalling pathways, and as substrates for membrane constituents. When LCFA uptake exceeds 
the capacity for their cardiac utilization, the intracellular lipids accumulate and are thought to contribute to contractile dys-
function, arrhythmias, cardiac myocyte apoptosis and congestive heart failure. Moreover, increased cardiac myocyte tria-
cylglycerol, diacylglycerol and ceramide depots are cardinal features associated with obesity and type 2 diabetes. In recent 
years considerable evidence has accumulated to suggest that, the rate of entry of long chain fatty acids (LCFAs) into the 
cardiac myocyte is a key factor contributing to a) regulating cardiac LCFA metabolism and b) lipotoxicity in the obese 
and diabetic heart. In the present review we i) examine the evidence indicating that LCFA transport into the heart involves 
a protein-mediated mechanism, ii) discuss the proteins involved in this process, including FAT/CD36, FABPpm and 
FATP1, iii) discuss the mechanisms involved in regulating LCFA transport by some of these proteins (including signaling 
pathways), as well as iv) the possible interactions of these proteins in regulating LCFA transport into the heart. In addi-
tion, v) we discuss how LCFA transport and transporters are altered in the obese/diabetic heart.  
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INTRODUCTION 
  Long chain fatty acids (LCFAs) provide 70-80% of the 
energy for cardiac contractile activity [1,2]. LCFAs are also 
essential for other processes, such as genetic reprogramming 
via activation of transcription factors regulating the tran-
scription of enzymes involved in lipid metabolism [3]. They 
serve as substrates for membrane synthesis and can modulate 
many intracellular signaling pathways [1,2]. Inside cardiac 
myocytes there is a limited capacity for lipid storage, and 
hence, the uptake and oxidation of LCFA are tightly coupled 
[2]. Although LCFA can enter the cells via simple diffusion 
[4-8], considerable evidence has accumulated in recent years 
showing that a protein-mediated mechanism is involved in 
the uptake of myocardial LCFA [for recent reviews see: 4, 9-
11]. Hence, there is a considerable interest in elucidating the 
regulation of LCFA movement into the myocardium via pro-
tein-mediated LCFA transporters. For both LCFA uptake 
and oxidation, specific LCFA binding proteins play a sub-
stantial role in facilitating LCFA movement across cellular 
membranes (plasma membranes and mitochondrial mem-
branes, respectively). Although the precise mode of action of 
these proteins is not yet known, for convenience they are 
referred to as LCFA transport proteins or LCFA transporters 
[4]. By regulating the rate of the entry of LCFAs into the 
cardiac myocytes, these LCFA transport proteins may serve 
as a key factor contributing to the regulation of LCFA me-
tabolism in healthy hearts, while in obesity and diabetes 
these proteins may contribute to the lipotoxicity associated 
with excess lipid accumulation in the heart. 
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  To date, it has been shown that myocardial expression of 
LCFA transporters is modulated through both transcriptional 
and post-transcriptional mechanisms [see review: 11]. An-
other level of regulation is the distribution of these transport-
ers between intracellular compartments and the plasma mem-
brane, which determines the myocardial capacity for LCFA 
uptake. Several LCFA transporters are expressed in the 
heart, including fatty acid translocase (FAT)/CD36, plasma 
membrane associated fatty acid binding protein (FABPpm) 
and fatty acid transport proteins 1 and 6 (FATP1 and 6) [12-
16]. Solid evidence confirming the roles of these various 
proteins as fatty acid transporters are based on genetic stud-
ies. In mice, ablation of myocardial FAT/CD36 reduced the 
rate of LCFA uptake and lowered the basal rates of LCFA 
esterification and oxidation in heart [17-19]. However, com-
pensatory substrate flexibility was observed, because FAT/ 
CD36-null hearts switched to glucose oxidation to sustain 
normal cardiac energetics [19]. Overexpression of FABPpm 
in skeletal muscle, via electrotransfection of the correspond-
ing cDNA into soleus muscle, increased the rate of LCFA 
transport into this muscle [20]. In cardiospecific FATP-1 
overexpressor mice, there were increased rates of palmitate 
esterification and oxidation, along with a decreased rate of 
glucose utilization [21], while in FATP1 KO mice, insulin-
stimulated triacylglycerol synthesis was blunted [22], and 
diet-induced insulin resistance was prevented [23]. Impor-
tantly, genetic approaches in Saccharomyces cerevisiae have 
shown that the transport capacities of the FATP isoforms 
differ markedly [24]. For example, the LCFA transport ca-
pacity of FATP-4 was greater than that of FATP-1, and the 
transport capacities of both FATP-1 and 4 greatly exceeded 
that of FATP-6 [24]. Thus, the LCFA transport role of 
FATP-6 in the heart may be less important than initial stud-
ies [25] had suggested. In general little is known about the 
physiologic regulation of FATPs in the heart, while consid-Protein-mediated Fatty Acid Uptake in the Heart  Current Cardiology Reviews, 2008, Vol. 4, No. 1    13
erably more is known about the regulation of FAT/CD36 in 
this organ. 
MYOCARDIAL UPTAKE AND METABOLISM OF 
LCFA 
  LCFA uptake into cardiac myocytes and their subsequent 
metabolism has been recently reviewed [9,10,26] and only a 
brief summary is presented here. As mentioned above, myo-
cardial LCFA uptake occurs by two different processes. 
First, based on the hydrophobic nature of LCFAs, they may 
traverse the lipid bilayer of the cardiac myocytes’ sar-
colemma by simple diffusion [4-7]. However, it has been 
shown that myocardial, protein-mediated LCFA transmem-
brane transport accounts for more than 70% of total cardiac 
LCFA uptake [17,19,27,28].  
  Little is currently known regarding the exact mechanism 
by which protein-mediated LCFA trafficking occurs across 
the plasma membrane. Possibly, these proteins function in 
trapping blood-borne LCFAs and transmembrane transloca-
tion of LCFA occurs by a flip-flop mechanism [4,9,10]. Kle-
infeld’s group has attempted to address this matter recently 
[8], but full details of the transmembrane LCFA movement 
process remain unknown. Presently, it is also unclear why 
there are a number of different LCFA transporters. They are 
derived from separate genes and are structurally unrelated 
[29-31]. It is not known whether there is one LCFA trans-
porting system involving the concerted action of all the fatty 
acid transporters, or alternatively, whether each of these pro-
teins is separately involved in transmembrane LCFA trans-
port, possibly targeting LCFAs to specific metabolic proc-
esses within the cell (Fig. (1)).  
  Once LCFAs have crossed the sarcolemma, they are 
transferred to cytoplasmic heart-type fatty acid-binding pro-
tein (H-FABPc). FABPs are small (15 kDa), highly con-
served cytoplasmic proteins that bind long-chain fatty acids 
with1:1molarstoichiometry and micromolar affinity [32,33]. 
This binding of LCFAs to the intracellular H-FABPc likely 
occurs through protein-protein interaction between FAT/ 
CD36 and H-FABPc, as both proteins coimmunoprecipitate 
in cellular lysates, at least in epithelial mammary gland cells 
[34]. The intracellular H-FABPc capacity for binding of 
LCFAs controls movement and concentration of this lipid 
fraction. Thus, binding with H-FABPc is an important player 
in cellular LCFA uptake. Data from FABPc KO mice sup-
port involvement of FABPc in shuttling the FA moieties 
from sarcolemma to the target sites of oxidation or esterifica-
tion [35-38]. Under normal circumstances FABPc is well in 
excess of the LCFAs transported into muscle cells [39]. 
  Mammals express multiple isoforms of acyl-CoA syn-
thetase (ACSL1 and ACSL3-6), and they are expressed dif-
ferentially in various tissues [40]. It has been postulated that 
these enzymes are essential for LCFA metabolism, providing 
activated intermediates for complex lipid synthesis and -
oxidation [41]. Interestingly, one of the LCFA transporters, 
namely FATP1, displays acyl-CoA synthetase activity [42, 
43], but this activity does not seem to account for the trans-
port activity of FATP1 or other FATPs [24]. Schaffer has 
speculated [44,45] that there may be fatty acyl-CoA syn-
thetases associated with FAT/CD36 on the cytosolic side of 
the sarcolemmal membrane. This direct (FATPs) or indirect 
(FAT/CD36) linkage of LCFA transporters and fatty acyl-
CoAs, indicates that a considerable portion of LCFAs trans-
ported across the membrane are rapidly esterified into fatty 
acyl-CoA. The latter process not only prevents backflux of 
LCFAs but also commits the esterified LCFAs (fatty acyl-
CoA) to further metabolism. These long-chain acyl-CoAs are 
immediately complexed with acyl-CoA binding proteins 
(ACBP)[46], which possess high affinity for long-chain fatty 
acyl-CoAs. ACBPs are indispensable for efficient trans-
cytoplasmic trafficking of long-chain fatty acyl-CoAs [35-
37,46]. The fate of intracellular fatty acyl-CoAs is largely 
determined by the rates of their transport into mitochondria, 
-oxidation, and Krebs cycle flux. In the heart cytosol, the 
complex of long-chain fatty acyl-CoA and ACBP is trans-
ported either into mitochondria for -oxidation (70-80%) or 
the fatty acyl-CoAs are esterified (10-30%) mainly to form 
triacylglycerols (TG) (Fig. (1)). 
Fig. (1). Schematic view of protein-mediated, long-chain fatty acid uptake and metabolism in cardiac myocytes. Abbreviations: FAT/CD36 -
fatty acid translocase; FABPpm - plasmalemmal fatty acid-binding protein; FABPc - cytoplasmic fatty acid-binding protein; FATP - fatty 
acid transport protein; ACBP - acyl-CoA binding protein; ACS - acyl-CoA synthetase. For clarity the scheme shows FAT/CD36 and FATP1 
to function independently, this however is not known for certain. 14 Current Cardiology Reviews, 2008, Vol. 4, No. 1 Chabowski et al. 
  Assuming that one potential mechanism of myocardial 
lipotoxicity may be the result of a mismatch between lipid 
oxidation and lipid uptake, it must be acknowledged that 
changes in mitochondrial LCFA oxidation may therefore 
affect triacyglycerol (TG) stores and lipid deposition. A pos-
sible role for FAT/CD36 in contribution to the regulation of 
mitochondrial LCFA utilization has been recently proposed 
as we [47,48] have found that FAT/CD36 is present in the 
mitochondrial membrane in skeletal muscles. Furthermore, 
during increased energy demands of the skeletal muscle 
(electrically-stimulated contraction or exercise) FAT/CD36 
was translocated, presumably from an endosomal pool to   
the mitochondria [47,49]. A functional role for FAT/CD36 
was strongly suggested, because sulfo-N-succinimidyl-oleate 
(SSO), a known covalent inhibitor of FAT/CD36 [28], al-
most fully inhibited mitochondrial fatty acid oxidation, either 
when muscle was at rest or had been contracting [47-49]. 
REGULATION OF CARDIAC LCFA UPTAKE  
 In  vivo, several factors have been implicated in the regu-
lation of the blood-borne LCFA entry into cardiac myocytes 
including (1) availability of exogenous substrates (substrate 
milieu); (2) hormone milieu (particularly insulin); (3) cardiac 
energy demands (workload/heart rate); and (4) an adequate 
oxygen supply.  
Regulation by the Hormonal Milieu 
  It has been shown that acute and chronic exposure to 
insulin favors LCFA uptake and subsequent esterification in 
cardiac myocytes [15]. Acute insulin exposure (30 min) 
stimulated the rate of LCFA transport into cardiac myocytes 
by inducing the translocation of only FAT/CD36, but not 
FABPpm nor FATP1, from an intracellular membrane com-
partment to the plasma membrane (Fig. (2)). This suggests 
that FABPpm and FATP-1 play minor or permissive roles in 
LCFA trans-sarcolemmal transport into cardiac myocytes 
when PI3 kinase is activated by insulin [12,13,15]. Chronic 
exposure of quiescent cardiac myocytes to insulin (2h) not 
only induced FAT/CD36 translocation, but also increased 
FAT/CD36 expression at the protein level [12] and Fig. (3).
An insulin-induced increase in plasmalemmal FAT/CD36
stimulated the rate of palmitate transport into cardiac myo-
cytes, which paralleled the increase in the content of myo-
cardial lipid pools (mainly PL and TG stores) [15]. 
  It has been suggested that other hormones are likely also 
involved in the regulation of intracellular lipid homeostasis. 
One of the most potent candidates includes leptin [50]. In 
isolated working rat hearts leptin increased the rate of palmi-
tate oxidation [44] but this effect appeared to occur inde-
pendently of the well-known leptin-induced activation of the 
AMPK-ACC-malonyl-CoA (AMP kinase and acetyl-CoA 
carboxylase) axis [51]. Interestingly, in our laboratory, we 
observed that leptin-induced stimulation of LCFA oxidation 
in cardiac myocytes is critically dependent on the leptin-
induced increase in LCFA transport via the translocation of 
FAT/CD36 [Bonen et al. unpublished observations].  
Regulation by Contraction and AMPK Activation 
  It is well known that myocardial energy metabolism and 
LCFA utilization are substantially increased [16] when the 
workload of the heart is increased or when quiescent cardiac 
myocytes are electrically stimulated to contract. Indeed, 
LCFA taken up into contracting cardiac myocytes were effi-
ciently channeled into mitochondrial -oxidation, while es-
terification into cellular lipid pools remained unaltered [16]. 
Recent studies have revealed that during electrically-induced 
contraction of cardiac myocytes, the translocation of FAT/ 
CD36 from intracellular pool(s) to the plasma membranes is 
a major mechanism responsible for the increase in LCFA 
uptake rate [16]. It was also demonstrated that the contrac-
tion-induced increase in FAT/CD36-mediated LCFA uptake 
was completely inhibited by SSO, confirming the involve-
ment of FAT/CD36 in the underlying mechanism of LCFA 
transmembrane transport [16,28].  
  Increased cardiac workload is known to stimulate com-
ponents of several intracellular signaling pathways [52,53]. 
Thus, the contraction-induced translocation of FAT/CD36, 
Fig. (2). Acute (30 min) effects of insulin (10 nM) and AMP kinase activation by AICAR (2 mM) on the content of plasmalemmal LCFA 
transporters (A) (FAT/CD36, FABPpm and FATP-1) and on the rate of palmitate transport (B) in rat cardiac myocytes (FAT/CD36, 
FABPpm and FATP-1) (Redrawn from data published by Chabowski et al. [13]). Protein-mediated Fatty Acid Uptake in the Heart  Current Cardiology Reviews, 2008, Vol. 4, No. 1    15
and subsequent increase in LCFA transport, might be linked 
to the activation of AMP kinase, protein kinase A (PKA), 
members of the protein kinase C (PKC) family, or mitogen-
activated protein kinase (MAPK). Our work has recently 
demonstrated that electrical stimulation of quiescent cardiac 
myocytes activates AMPK, which results in the translocation 
of FAT/CD36 to the plasma membrane and a concurrent 
increase in the rate of LCFA transport [16]. Similarly, phar-
macological AMPK activation in perfused heart, by contrac-
tion-mimetic compounds (5-aminoimidazole-4-carboxamide-
1-ß-D-ribofuranoside-AICAR) induced the translocation of 
both FAT/CD36 and FABPpm to the plasma membrane, and 
as a result, LCFA transport was increased [13,54]. Both 
transporters appeared to contribute to the AICAR-mediated 
increase in LCFA uptake (Fig. (2)). However, this notion is 
complicated by the observation that the FAT/CD36 inhibitor 
SSO completely blocked the AICAR-induced LCFA uptake, 
suggesting that the FABPpm component in AICAR-induced 
LCFA uptake is dependent on FAT/CD36 [54]. Furthermore, 
we have recent evidence suggesting a direct interaction   
between FAT/CD36 and FABPpm at the myocardial sar-
colemma [Chabowski A and Bonen A unpublished observa-
tions]. These observations seem to imply that when cellular 
energydemandsarechallenged(AMP/ATPratiois increased), 
the LCFA transport system is activated by means of translo-
cation of both transporters (FAT/CD36 and FABPpm) to the 
sarcolemma, which results in greater LCFA influx, which 
allows more LCFAs to be delivered to mitochondria. Thus, 
an increased rate of LCFA transport serves to provide the 
necessary substrate supply to support an increase in mito-
chondrial -oxidation in the heart.  
Alternate Signaling Pathways 
 While  insulin  signaling,  via the activation of PI3-kinase 
[15] and AMPK activation by contraction [16] provide sig-
nals for increasing LCFA transport, it is now also possible to 
exclude several signaling pathways in stimulating LCFA 
transport. Specifically, we have recently shown that cyclic 
AMP dependent protein kinase A (PKA) is not involved in 
regulating LCFA uptake by FAT/CD36 [55] because, in qui-
escent cardiac myocytes, pharmacologically-increased levels 
of intramyocardial cAMP failed to stimulate the transloca-
tion of LCFA transporters. It also appears that the MAPK 
signaling cascade is not involved in the acute regulation of 
LCFA transporter translocation and subsequent LCFA myo-
cardial uptake [56]. However, separate stimulation of PKC 
by the phorbol ester 12-myristate 13-acetate (PMA) resulted 
in an increased rate of LCFA uptake in isolated cardiac myo-
cytes; this effect was blunted by SSO, indicating that certain 
PKC isoforms enhance LCFA uptake in a CD 36-dependent 
manner [55]. Clearly, the signaling pathways involved in 
Fig. (3). Chronic (2h) effects of insulin (10 nM) and AMP kinase activation by AICAR (2 mM) on the transcription (mRNA), total protein 
and plasmalemmal expression of FAT/CD36 and FABPpm in isolated rat cardiac myocytes. (Redrawn from data published by Chabowski et 
al. [12,54]). 16 Current Cardiology Reviews, 2008, Vol. 4, No. 1 Chabowski et al. 
recruiting LCFA transporters to the cell surface are only now 
beginningtobeexplored.Itwill be important to deduce which 
signaling pathways are important and whether there are dif-
ferent signaling pathways for different LCFA transporters. 
Adequate Oxygen Supply and LCFA Myocardial Me-
tabolism 
  Myocardial metabolism of LCFA is highly dependent on 
adequateoxygen supply. In the ischemic myocardium, LCFA 
are diverted from -oxidation into deposition as neutral in-
tracellular lipids within the tissue [57,58]. This myocardial 
lipid accumulation during hypoxia could be at least partially 
due to the mismatch between a reduced rate of -oxidation 
and the increased rate of LCFA transport into cardiac myo-
cytes, the latter occurring as a result of the low oxygen-
induced translocation of FAT/CD36 and FABPpm to the 
plasma membrane [59] and Fig. (4). Lipid accumulation in 
the ischemic heart is likely also related to the switch in en-
ergy substrate preference from the predominant oxidation of 
LCFA occurring in healthy heart to the increased utilization 
of glucose during heart failure [2,60,61]. This is the case 
when cardiac myocytes are exposed to a lower oxygen sup-
ply over a prolonged period of time. It has been suggested 
that there is a direct involvement of LCFA transporters in the 
transition away from LCFA metabolism in long-term heart 
failure [62]. For example, in infarcted rat hearts, an animal 
model of heart failure, there are parallel reductions in the 
total content of LCFA transporters (FAT/CD36, FABPpm, 
FATP-1 and FATP-6) and palmitate oxidation, along with  
a concomitantly reduced cardiac ejection fraction [62]. A 
marked decrease in myocardial LCFA oxidation was also 
observed in FAT/CD36 null mice, suggesting that there was 
a significant energy impairment (decreased ATP production) 
when hearts were challenged with low-flow ischemia [18]. 
However, a recent study strongly points to the fact that 
FAT/CD36 deficient hearts are not energetically or function-
ally impaired, most likely due to compensatory increase in 
glucose oxidation. Importantly, FAT/CD36 deficient hearts, 
after low-flow ischemia, recovered to the same extent as 
wild type hearts [19]. 
Regulation of Protein-Mediated LCFA Transport by 
Substrate Milieu  
  Cardiovascular abnormalities remain the leading cause of 
mortality in individuals with obesity and obesity related type 
2 diabetes. It is widely accepted that hyper-and/or hypo- in-
sulinemia, hyperglycemia, and increased plasma LCFA 
and/or lipoprotein concentrations are associated with obesity 
and type 2 diabetes, and may negatively influence myocar-
dial performance [26,63,64]. 
  Blood plasma concentrations of metabolic substrates 
have a significant impact on myocardial metabolism [65], 
because it is known that selected substrates can regulate the 
expression of specific metabolic genes [66-69]. LCFA`s are 
known ligands for the peroxisome proliferator-activated re-
ceptors (PPARs), which regulate genes involved in fatty acid 
metabolism [70,71]. Consistent with their roles in LCFA 
transport, LCFA transporters appear to be upregulated when 
the LCFA milieu is increased by a high fat diet or by fasting 
[72]. For example, FAT/CD36 mRNA was upregulated in 
neonatal cardiac myocytes after a 48 h exposure to high con-
centrations (0.25 mM) of palmitate [73]. Moreover, recent 
findings indicate that in quiescent cardiac myocytes palmi-
tate exposure (2h) (0.1-1mM) also resulted in an increased 
expression of FAT/CD36 protein, which appeared to be due 
to posttranscriptional events [Chabowski A et al. unpub-
lished data].  
  Data obtained from rodent studies suggest that in health, 
the balance between the myocardial utilization of the main 
metabolic substrates is finely tuned (i.e. LCFA ~70% and 
glucose ~30%). This, however is disturbed in cardiac dis-
ease, so that a marked preference for largely a single sub-
strate (glucose or LCFA) arises, which can result in cardiac 
malfunctioning [26]. Specifically, altered myocardial sub-
strate metabolism, namely reduced rates of glucose use (gly-
colysis and glucose oxidation) with a concomitant increase 
in rates of LCFA oxidation are primarily responsible for dia-
betic cardiomyopathies [26,74-77]. Furthermore, since it was 
shown that, disturbance in cardiac myocyte lipid utilization 
preceded the development of cardiomyopathy, it appears that 
Fig. (4). Changes in fatty acid transporters (FAT/CD36 and FABPpm) plasmalemmal content and FA transport (A) and oxidation induced by 
acute hypoxia (15 min) (B). PM- plasma membranes, LDM-low density microsomes. (Redrawn from data published by Chabowski et al..
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despite increases in LCFA oxidation, lipid accumulation 
predominates and in the myocardium plays a central role in 
the etiology of diabetic cardiomyopathy [78,79]. It has be-
come evident that when the LCFAs supply exceeds the 
heart’s capacity for their utilization, accumulation of intra-
cellular lipids leads to arrhythmias, cardiac myocyte apopto-
sis and congestive heart failure. For instance, Schaffer’s 
group [80] has demonstrated that the mismatch in LCFA 
uptake and oxidation (uptake >> metabolism) contributed to 
lipotoxicity in the heart, resulting in cardiac triacylglycerol 
accumulation, and left ventricular dysfunction and pre-
mature death. Thus, therapies aimed at removing the excess 
of intracellular LCFA from the cytosol should be beneficial, 
since high concentrations of myocardial LCFA are detrimen-
tal to proper cardiac functioning [81,82].  
CARDIAC FATTY ACID TRANSPORTERS IN DIA-
BETES, INSULIN RESISTANCE AND OBESITY 
  The pathogenesis of type 2 diabetes and insulin resis-
tance have both genetic and environmental (diet, physical 
activity) contributions. Animal genetic models of the type2 
diabetes almost exclusively involve leptin disruption or its 
receptor dysfunction [for review: 63]. Models of insulin re-
sistance (e.g. high-fat or high-carbohydrate diets) result only
in mild hyperglycemia [83,84]. Nevertheless in these models 
cardiac LCFA oxidation is altered. For example, in type 2 
diabetic animal models, such as db/db or insulin resistant 
ob/ob mice the data consistently point to an increased FA 
oxidation in heart [75-77]. This is also found in and Zucker 
diabetic fatty rats [85]. It has also been noted that there is an 
increased intracellular TG content in the hearts of ob/ob mice 
and ZDF rats [86]. Collectively, these studies strongly imply 
that there is an imbalance between FA oxidation and fatty 
acid uptake in the heart of diabetic animal models. This has 
now been shown in several studies. In skeletal muscle and 
hearts of type 2 diabetic rats and mice, fatty acid transport 
rates were increased as a consequence of an increased plas-
malemmal FAT/CD36 content [74, 92]. That fatty acid 
transporters were the key factor in upregulating LCFA oxi-
dation in hearts of type 2 diabetic db/db mice was recently 
shown. In these mice, it was the increase in plasmalemmal 
FAT/CD6 and FABPpm that accounted for the increased 
rates of LCFA esterification and oxidation, since no differ-
ences in any other parameters in LCFA metabolism were 
apparent in this model of type 2 diabetes Fig. (6) and [92]. 
  In a model of obesity and insulin resistance, namely 
obese Zucker fa/fa rats, TGs and ceramides accumulate in 
the heart. This is not only the consequence of an increase in 
plasma lipids, but is also attributable to the shift in cardiac 
LCFA metabolism. In this model of obesity LCFA uptake 
into the myocyte is increased, LCFA oxidation is not altered 
while LCFA esterification is markedly increased [78]. Con-
currently, glucose and lactate oxidation are inhibited [78]. 
This type of substrate switch, such as occurs in obese Zucker 
rats, was shown to be associated with the development of 
contractile dysfunction [78]. Chronically increased FA utili-
zation is thought to contribute to ventricular dysfunction by 
increasing mitochondrial oxygen consumption, generation of 
reactive species due to increased flux through oxidative 
pathways, or via the toxic effects of accumulated lipid spe-
cies [78-80]. A role for fatty acid transporters in obesity-
related myocardial lipid accumulation is evident in obese 
Zucker rats. For example, in insulin resistant, obese Zucker 
rats we found that myocardial FAT/CD36 protein expression 
was not altered, but instead it was permanently relocated to 
the cardiomyocyte plasma membrane, leading to an increase 
in LCFA transport and subsequent channeling of LCFA into 
triacylglycerols Fig. (5) and [90]. Thus, cardiac myocyte 
lipotoxicity likely is the result of LCFA uptake being in ex-
cessofitsdisposalrate(utilization) through oxidation, thereby 
leading to excessive lipid accumulation [90]. 
  Another animal model that exhibit myocyte lipid accu-
mulation and cardiac dysfunction has recently been des-
cribed [87]. In this model mice with cardiac-specific over-
expression of PPAR present enhanced expression of FA 
metabolizing genes with a concomitant increase in FA oxida-
tion. These alterations resemble those in animal models of 
obesity and diabetes. Furthermore, cardiomyopathy in this 
model can be exacerbated by increasing the circulating non-
esterified fatty acids (high fat diet) [88] or by diminishing 
FAT/CD36 (this increases circulating fatty acids), when 
MHC-PPAR mice were crossed with mice deficient for 
CD36 [89]. 
  We have also examined the effects of two levels of STZ-
induced diabetes (moderate and severe) on LCFA transport 
and LCFA transporter (FAT/CD36 and FABPpm) expres-
sion, at the mRNA and protein level, as well as their plas-
malemmal localization [91]. These studies have shown that 
with STZ-induced diabetes LCFA transport across the 
plasma membrane is increased in heart in relation to the se-
verity of insulin deficiency (severe diabetes > mild diabetes). 
These increases in LCFA transport in heart were associated 
with concomitant increases in the expression of FAT/CD36 
and FABPpm proteins, which resulted in the increased pres-
ence of FAT/CD36 (moderate and severe diabetes) and 
FABPpm (severe diabetes only) at the sarcolemma [91]. 
  Collectively, a number of studies have clearly shown the 
importance of LCFA transporters in regulating LCFA uptake 
and metabolism in the heart, in models of type 1 and type 2 
diabetes, and in obesity. It is however difficult to determine 
whether the increases in sarcolemmal LCFA transporters, 
and the subsequent enhancement in LCFA transport, are re-
lated to hyperglycemia or hypoinsulinemia, or to other sys-
temic factors that are disturbed, since in vivo a great many 
factors contribute to the regulation of lipid metabolism. Nev-
ertheless, Chen et al. [93] have recently implicated hyper-
glycemia as a key factor, since vanadate-induced normaliza-
tion of circulating glucose in STZ-induced diabetic rats, re-
sulted in a significant reduction in FAT/CD36 mRNA abun-
dance [93]. Similarly, Griffin et al. have shown increased 
translation of macrophage CD36 transcript under high glu-
cose conditions [94]. A better understanding of how the in-
dependent or combined availability of substrates (LCFA, 
glucose, lactate) regulate the expression and subcellular lo-
calization of LCFA transporters in the heart remains to be 
established.  
CARDIAC FATTY ACID TRANSPORTERS AND 
CARDIOVASCULAR DISEASES IN HUMANS 
  Based on data from rodent models, human gene CD36 
mutations have been implicated to play a causal role in im-18 Current Cardiology Reviews, 2008, Vol. 4, No. 1 Chabowski et al. 
pairment of insulin action. A relatively high frequency poly-
morphism in human FAT/CD36 occurs in Asian and African 
populations, and these have been associated with reductions 
in LCFA myocardial uptake and associated cardiac abnor-
malities [95,96]. For example, in CD36-deficient patients a 
high correlation was found between the reduction in the up-
take of the iodinated LCFA analogue BMIPP into the heart 
and the increase in glucose oxidation [97-100]. Paradoxi-
cally, it has also been shown that human CD36 deficiency 
co-exists with insulin resistance [97]. However, these studies 
in humans are limited and confusing, as essentially FAT/ 
CD36 overexpression in rodent models has commonly been 
linked to intracellular lipid accumulation, and therefore, one 
would expect that an FAT/CD36 deficiency might contribute 
to limiting intracellular lipid storage. One possibility is that 
the observed insulin resistance in these patients is associated 
with an increased hepatic uptake of LCFAs, involving fatty 
acid transporters other than FAT/CD36 [101,102].  
SUMMARY
  LCFA transporters (FAT/CD36 and FABPpm) play a 
pivotal role in the transport of LCFAs across the plasma 
membrane and thereby these proteins contribute to the regu-
lation of energy provision in cardiac muscle cells. In addi-
tion, it is likely that cardiac myocyte lipotoxicity is associ-
ated with either the increased expression of LCFA transport-
ers and/or with their permanent relocation to the plasma 
membrane. This is the case when LCFA oxidation rates re-
main constant or are enhanced but not in proportion to the 
increased rates of LCFA transport (i.e. transport > oxida-
tion). Thus, additional studies are needed to better under-
stand the regulation of LCFA uptake into the myocardium 
Fig. (6). Cardiac fatty acid uptake and metabolism in db/+ and db/db mice (A) and selected factors known to influence fatty acid oxidation 
(B). Note that the only factor accounting for the increased rate of fatty acid oxidation is the content of plasma membrane FAT/CD36 (data 
redrawn from Carley et al. [92]). 
Fig. (5). Changes in fatty acid transport, and FAT/CD36 and FABPpm protein expression and plasmalemmal content in hearts of obese 
Zucker rats. For each parameter the control has been set to 100%. Note that fatty acid transporter expression is not altered but that fatty acid 
transport is up regulated in concert with an increase in plasmalemmal FAT/CD36, indicating that FAT/CD36 is permanently relocated to the 
plasma membrane (obese Zucker rat). (Redrawn from data published by Coort et al. [90] and Luiken et al. [103]). Protein-mediated Fatty Acid Uptake in the Heart  Current Cardiology Reviews, 2008, Vol. 4, No. 1    19
and the subsequent partitioning between oxidative and non-
oxidative metabolic pathways. 
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